Phreesia (NYSE:PHR) Price Target Lowered to $14.00 at Needham & Company LLC

Key Points

• Needham & Company cut its Phreesia price target from $35 to $14 while maintaining a "buy" rating, with the new target implying roughly a 22% upside from the prior close.
• Phreesia missed Q4 EPS ($0.02 vs. $0.07 expected), lowered FY2027 revenue guidance to $510–$520M and cited headwinds from its network solutions business and the AccessOne integration, triggering an approximately 22% share plunge.
• Despite recent cuts, the MarketBeat consensus is still a "Moderate Buy" with a consensus price target of $27.41, and institutional investors own about 92% of the stock.

Phreesia (NYSE:PHR - Get Free Report) had its price target decreased by research analysts at Needham & Company LLC from $35.00 to $14.00 in a report released on Tuesday. The brokerage presently has a "buy" rating on the stock. Needham & Company LLC's target price points to a potential upside of 22.44% from the stock's previous close.

PHR has been the subject of a number of other reports. Royal Bank Of Canada began coverage on shares of Phreesia in a research note on Friday, January 9th. They issued a "moderate buy" rating and a $26.00 price objective for the company. Wells Fargo & Company decreased their price target on Phreesia from $30.00 to $25.00 and set an "overweight" rating on the stock in a report on Thursday, March 26th. DA Davidson dropped their price objective on Phreesia from $35.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, January 23rd. JPMorgan Chase & Co. lowered their price target on Phreesia from $29.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 20th. Finally, Robert W. Baird lowered their price objective on Phreesia from $31.00 to $25.00 and set an "outperform" rating for the company in a research note on Wednesday, December 10th. Seventeen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.41.

Phreesia Price Performance

Shares of Phreesia stock opened at $11.43 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia has a one year low of $10.75 and a one year high of $32.76. The stock has a market capitalization of $689.36 million, a P/E ratio of -114.33 and a beta of 0.67. The business's 50 day simple moving average is $12.51 and its two-hundred day simple moving average is $17.68.

Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.05). The company had revenue of $127.07 million for the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The company's revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.11) EPS. Analysts forecast that Phreesia will post -1.1 EPS for the current year.

Insider Buying and Selling at Phreesia

In related news, SVP Amy Beth Vanduyn sold 2,202 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total transaction of $36,024.72. Following the completion of the sale, the senior vice president owned 157,349 shares of the company's stock, valued at $2,574,229.64. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Allison C. Hoffman sold 6,176 shares of the company's stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $11.97, for a total value of $73,926.72. Following the transaction, the general counsel directly owned 163,485 shares in the company, valued at approximately $1,956,915.45. The trade was a 3.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 70,358 shares of company stock worth $1,123,569 over the last quarter. Insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On Phreesia

Several institutional investors and hedge funds have recently modified their holdings of PHR. Vanguard Group Inc. boosted its holdings in shares of Phreesia by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company's stock worth $134,177,000 after purchasing an additional 437,462 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Phreesia by 727.1% in the third quarter. New York State Common Retirement Fund now owns 136,856 shares of the company's stock valued at $3,219,000 after purchasing an additional 120,309 shares during the last quarter. Squarepoint Ops LLC lifted its position in Phreesia by 243.6% during the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company's stock worth $2,872,000 after buying an additional 71,553 shares in the last quarter. Greenhouse Funds LLLP lifted its position in Phreesia by 16.8% during the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company's stock worth $91,317,000 after buying an additional 557,265 shares in the last quarter. Finally, Bessemer Group Inc. boosted its stake in Phreesia by 1,065.9% during the third quarter. Bessemer Group Inc. now owns 554,513 shares of the company's stock worth $13,043,000 after buying an additional 506,954 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Company reported positive GAAP net income and strong free cash flow for the fiscal year — exceeded internal targets including crossing $100M of Adjusted EBITDA and roughly $50M+ of free cash flow, a proof point for profitability and capital-generation that can support valuation. Phreesia Announces Fourth Quarter Fiscal 2026 Results
• Positive Sentiment: Management highlighted record revenue growth and strategic initiatives on the Q4 call, indicating underlying demand and execution on product/partnership priorities that investors view as longer-term upside. Phreesia Inc (PHR) Q4 2026 Earnings Call Highlights: Record Revenue Growth and Strategic ...
• Neutral Sentiment: Full earnings-call transcript is available for detail seekers — useful for investors who want management’s color on drivers, margin improvement, and the AccessOne integration timeline. Phreesia, Inc. (PHR) Q4 2026 Earnings Call Transcript
• Neutral Sentiment: Several analysts revised expectations heading into the print, lowering EPS/forecast assumptions — shows sentiment was already shifting and likely amplified intraday moves. Top Wall Street Forecasters Revamp Phreesia Expectations Ahead Of Q4 Earnings
• Negative Sentiment: Management cut near-term outlook: FY2027 revenue was guided to $510M–$520M and executives warned of headwinds from the network solutions business and integration-related pressure from AccessOne — a driver of the recent sell-off. Phreesia outlines $510M–$520M revenue target for 2027 amid network solutions headwinds and AccessOne integration
• Negative Sentiment: Market reaction: shares plunged after the EPS miss and guidance cut (reports of a ~22% drop and all-time lows in some sessions) — short-term momentum and sentiment risk remain. Phreesia shares tumble 22% on earnings miss, slashed guidance

Phreesia Company Profile

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.